Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Care | Research article

Smoking cessation care can translate to lower hazard of death in the short-run in cancer patients - a retrospective cohort study to demonstrate the value of smoking cessation services within the treatment phase of cancer

Authors: F. I. Hawari, N. A. Obeidat, D. Rimawi, K. Jamal

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Smoking cessation is a key step towards improving cancer care and outcomes. However, smoking cessation interventions are underprovided in oncology settings. Within Jordan’s only comprehensive oncology center, we sought to evaluate receipt of care at a smoking cessation clinic and the effect of assisted abstinence through the smoking cessation clinic on short-term (two-year) survival after a cancer diagnosis.

Methods

We employed a retrospective cohort study design. Cancer registry and smoking cessation clinic data for adult Jordanian cancer patients diagnosed between 2009 and 2016, who also were cigarette smokers, and who received full treatment at King Hussein Cancer Center, were analyzed. Specifically, descriptive statistics of patients who visited the smoking cessation clinic were generated, and short-term (two-year) hazard of death of patients based on whether or not smoking cessation clinic-assisted abstinence occurred, were evaluated.

Results

There were 3403 patients who met our inclusion criteria. Approximately 21% of cancer patients were seen at the smoking cessation clinic, and significant demographic and clinical disparities in who was being seen [at the smoking cessation clinic] existed. In 2387 patients with available survival data, smokers who never went to the smoking cessation clinic (or were seen only once, or seen a year or more from diagnosis) had a hazard of death 2.8 times higher than smokers who had visited the smoking cessation clinic and who also confirmed they had not smoked on atleast two of their 3-, 6- or 12-month follow-up visits (95% confidence interval [CI] = 1.7–4.6). Non-abstainers at the smoking cessation clinic exhibited a similar disadvantage (HR 2.7, 95% CI 1.4–5.0).

Conclusions

Although evidence-based smoking cessation interventions increase the likelihood of abstinence and can lower the short-term hazard of death during cancer treatment, there is a deprioritization of smoking cessation interventions during cancer care, as indicated by low proportions of patients seen at the smoking cessation clinic. Our findings emphasize the importance of promoting interventions to avail smoking cessation interventions in oncology settings within the cancer treatment phase.
Literature
1.
go back to reference Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martinez GA, Frenel JS, Karamouzis M, et al. Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO open. 2018;3(2):e000285.CrossRef Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martinez GA, Frenel JS, Karamouzis M, et al. Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO open. 2018;3(2):e000285.CrossRef
2.
go back to reference Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: an overview for clinicians. CA Cancer J Clin. 2014;64(4):272–90.CrossRef Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: an overview for clinicians. CA Cancer J Clin. 2014;64(4):272–90.CrossRef
3.
go back to reference Gritz ER, Toll BA, Warren GW. Tobacco use in the oncology setting: advancing clinical practice and research. Cancer Epidemiol Biomarkers Prev. 2014;23(1):3–9.CrossRef Gritz ER, Toll BA, Warren GW. Tobacco use in the oncology setting: advancing clinical practice and research. Cancer Epidemiol Biomarkers Prev. 2014;23(1):3–9.CrossRef
4.
go back to reference Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon TH, et al. Research priorities, measures, and recommendations for assessment of tobacco use in clinical Cancer research. Clin Cancer Res. 2016;22(8):1907–13.CrossRef Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon TH, et al. Research priorities, measures, and recommendations for assessment of tobacco use in clinical Cancer research. Clin Cancer Res. 2016;22(8):1907–13.CrossRef
5.
go back to reference Burcu M, Steinberger EK, Sorkin JD. Health care access and smoking cessation among cancer survivors: implications for the affordable care act and survivorship care. J Cancer Surviv. 2016;10(1):1–10.CrossRef Burcu M, Steinberger EK, Sorkin JD. Health care access and smoking cessation among cancer survivors: implications for the affordable care act and survivorship care. J Cancer Surviv. 2016;10(1):1–10.CrossRef
6.
go back to reference Ostroff JS, Goffin JR, Khuri FR, Warren GW. Perspective on the National Comprehensive Cancer Network's clinical practice guidelines for smoking cessation. J Oncol Pract. 2016;12(1):55–8.CrossRef Ostroff JS, Goffin JR, Khuri FR, Warren GW. Perspective on the National Comprehensive Cancer Network's clinical practice guidelines for smoking cessation. J Oncol Pract. 2016;12(1):55–8.CrossRef
7.
go back to reference Fiore MC, Adsit R. Will hospitals finally "do the right thing"? Providing evidence-based tobacco dependence treatments to hospitalized patients who smoke. Jt Comm J Qual Patient Saf. 2016;42(5):207–8.CrossRef Fiore MC, Adsit R. Will hospitals finally "do the right thing"? Providing evidence-based tobacco dependence treatments to hospitalized patients who smoke. Jt Comm J Qual Patient Saf. 2016;42(5):207–8.CrossRef
8.
go back to reference Lucchiari C, Masiero M, Botturi A, Pravettoni G. Helping patients to reduce tobacco consumption in oncology: a narrative review. SpringerPlus. 2016;5(1):1136.CrossRef Lucchiari C, Masiero M, Botturi A, Pravettoni G. Helping patients to reduce tobacco consumption in oncology: a narrative review. SpringerPlus. 2016;5(1):1136.CrossRef
9.
go back to reference Chang EHE, Braith A, Hitsman B, Schnoll RA. Treating nicotine dependence and preventing smoking relapse in Cancer patients. Expert Rev Qual Life Cancer Care. 2017;2(1):23–39.CrossRef Chang EHE, Braith A, Hitsman B, Schnoll RA. Treating nicotine dependence and preventing smoking relapse in Cancer patients. Expert Rev Qual Life Cancer Care. 2017;2(1):23–39.CrossRef
10.
go back to reference Kaiser EG, Prochaska JJ, Kendra MS. Tobacco cessation in oncology care. Oncology. 2018;95(3):129–37.CrossRef Kaiser EG, Prochaska JJ, Kendra MS. Tobacco cessation in oncology care. Oncology. 2018;95(3):129–37.CrossRef
11.
go back to reference Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2014;65(4):742–54.CrossRef Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2014;65(4):742–54.CrossRef
12.
go back to reference Florou AN, Gkiozos IC, Tsagouli SK, Souliotis KN, Syrigos KN. Clinical significance of smoking cessation in subjects with cancer: a 30-year review. Respir Care. 2014;59(12):1924–36.CrossRef Florou AN, Gkiozos IC, Tsagouli SK, Souliotis KN, Syrigos KN. Clinical significance of smoking cessation in subjects with cancer: a 30-year review. Respir Care. 2014;59(12):1924–36.CrossRef
13.
go back to reference McCarter K, Martinez U, Britton B, Baker A, Bonevski B, Carter G, Beck A, Wratten C, Guillaumier A, Halpin SA, et al. Smoking cessation care among patients with head and neck cancer: a systematic review. BMJ Open. 2016;6(9):e012296.CrossRef McCarter K, Martinez U, Britton B, Baker A, Bonevski B, Carter G, Beck A, Wratten C, Guillaumier A, Halpin SA, et al. Smoking cessation care among patients with head and neck cancer: a systematic review. BMJ Open. 2016;6(9):e012296.CrossRef
14.
go back to reference Hawari FI, Nazer LH, Addassi A, Rimawi D, Jamal K. Predictors of ICU admission in patients with Cancer and the related characteristics and outcomes: a 5-year registry-based study. Crit Care Med. 2016;44(3):548–53.CrossRef Hawari FI, Nazer LH, Addassi A, Rimawi D, Jamal K. Predictors of ICU admission in patients with Cancer and the related characteristics and outcomes: a 5-year registry-based study. Crit Care Med. 2016;44(3):548–53.CrossRef
15.
go back to reference Curtis A, Ondracek RP, Murekeyisoni C, Kauffman E, Mohler J, Marshall J. Tobacco use and outcome in radical prostatectomy patients. Cancer Med. 2017;6(4):857–64.CrossRef Curtis A, Ondracek RP, Murekeyisoni C, Kauffman E, Mohler J, Marshall J. Tobacco use and outcome in radical prostatectomy patients. Cancer Med. 2017;6(4):857–64.CrossRef
16.
go back to reference Sharp L, McDevitt J, Brown C, Carsin AE, Comber H. Association between smoking at diagnosis and cause-specific survival in patients with rectal cancer: results from a population-based analysis of 10,794 cases. Cancer. 2017;123(13):2543–50.CrossRef Sharp L, McDevitt J, Brown C, Carsin AE, Comber H. Association between smoking at diagnosis and cause-specific survival in patients with rectal cancer: results from a population-based analysis of 10,794 cases. Cancer. 2017;123(13):2543–50.CrossRef
17.
go back to reference Tabuchi T, Goto A, Ito Y, Fukui K, Miyashiro I, Shinozaki T. Smoking at the time of diagnosis and mortality in cancer patients: what benefit does the quitter gain? Int J Cancer. 2017;140(8):1789–95.CrossRef Tabuchi T, Goto A, Ito Y, Fukui K, Miyashiro I, Shinozaki T. Smoking at the time of diagnosis and mortality in cancer patients: what benefit does the quitter gain? Int J Cancer. 2017;140(8):1789–95.CrossRef
18.
go back to reference Tamakoshi A, Nakamura K, Ukawa S, Okada E, Hirata M, Nagai A, Matsuda K, Kamatani Y, Muto K, Kiyohara Y, et al. Characteristics and prognosis of Japanese colorectal cancer patients: the BioBank Japan project. J Epidemiol. 2017;27(3s):S36–s42.CrossRef Tamakoshi A, Nakamura K, Ukawa S, Okada E, Hirata M, Nagai A, Matsuda K, Kamatani Y, Muto K, Kiyohara Y, et al. Characteristics and prognosis of Japanese colorectal cancer patients: the BioBank Japan project. J Epidemiol. 2017;27(3s):S36–s42.CrossRef
19.
go back to reference Japuntich SJ, Kumar P, Pendergast J, Juarez, Caballero GY, Malin J, Wallace R, Chrischilles E, Keating NL, Park ER. Smoking status and survival among a national cohort of lung and colorectal cancer patients. Nicotine Tob Res. 2019;21(4):497–504.CrossRef Japuntich SJ, Kumar P, Pendergast J, Juarez, Caballero GY, Malin J, Wallace R, Chrischilles E, Keating NL, Park ER. Smoking status and survival among a national cohort of lung and colorectal cancer patients. Nicotine Tob Res. 2019;21(4):497–504.CrossRef
20.
go back to reference Ordonez-Mena JM, Walter V, Schottker B, Jenab M, O'Doherty MG, Kee F, Bueno-de-Mesquita B, Peeters PHM, Stricker BH, Ruiter R, et al. Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortium. Ann Oncol. 2018;29(2):472–83.CrossRef Ordonez-Mena JM, Walter V, Schottker B, Jenab M, O'Doherty MG, Kee F, Bueno-de-Mesquita B, Peeters PHM, Stricker BH, Ruiter R, et al. Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the CHANCES consortium. Ann Oncol. 2018;29(2):472–83.CrossRef
21.
go back to reference Goldstein AO, Ripley-Moffitt CE, Pathman DE, Patsakham KM. Tobacco use treatment at the U.S. National Cancer Institute's designated Cancer centers. Nicotine Tob Research. 2013;15(1):52–8.CrossRef Goldstein AO, Ripley-Moffitt CE, Pathman DE, Patsakham KM. Tobacco use treatment at the U.S. National Cancer Institute's designated Cancer centers. Nicotine Tob Research. 2013;15(1):52–8.CrossRef
22.
go back to reference Warren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, Dibaj S, Herbst R, Mulshine JL, Hanna N, et al. Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. J Oncol Pract. 2013;9(5):258–62.CrossRef Warren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, Dibaj S, Herbst R, Mulshine JL, Hanna N, et al. Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. J Oncol Pract. 2013;9(5):258–62.CrossRef
23.
go back to reference Obeidat NA, Ayub HS, Amarin R, Aburajab Altamimi B, Ghonimat I, Abughosh S, Hawari FI. Smoking cessation support among oncology practitioners in a regional Cancer Center in the Middle East-Improving a critical Service for Cancer Care. Oncologist. 2016;21(4):503–5.CrossRef Obeidat NA, Ayub HS, Amarin R, Aburajab Altamimi B, Ghonimat I, Abughosh S, Hawari FI. Smoking cessation support among oncology practitioners in a regional Cancer Center in the Middle East-Improving a critical Service for Cancer Care. Oncologist. 2016;21(4):503–5.CrossRef
24.
go back to reference Peters EN, Warren GW, Sloan JA, Marshall JR. Tobacco assessment in completed lung cancer treatment trials. Cancer. 2016;122(21):3260–2.CrossRef Peters EN, Warren GW, Sloan JA, Marshall JR. Tobacco assessment in completed lung cancer treatment trials. Cancer. 2016;122(21):3260–2.CrossRef
26.
go back to reference Cheung KL, de Ruijter D, Hiligsmann M, Elfeddali I, Hoving C, Evers S, de Vries H. Exploring consensus on how to measure smoking cessation. A Delphi study. BMC Public Health. 2017;17(1):890.CrossRef Cheung KL, de Ruijter D, Hiligsmann M, Elfeddali I, Hoving C, Evers S, de Vries H. Exploring consensus on how to measure smoking cessation. A Delphi study. BMC Public Health. 2017;17(1):890.CrossRef
27.
go back to reference Velicer WF, Prochaska JO. A comparison of four self-report smoking cessation outcome measures. Addict Behav. 2004;29(1):51–60.CrossRef Velicer WF, Prochaska JO. A comparison of four self-report smoking cessation outcome measures. Addict Behav. 2004;29(1):51–60.CrossRef
28.
go back to reference Tran BT, Halperin A, Chien JW. Cigarette smoking and outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(7):1004–11.CrossRef Tran BT, Halperin A, Chien JW. Cigarette smoking and outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(7):1004–11.CrossRef
29.
go back to reference Ehlers SL, Gastineau DA, Patten CA, Decker PA, Rausch SM, Cerhan JR, Hogan WJ, Ebbert JO, Porrata LF. The impact of smoking on outcomes among patients undergoing hematopoietic SCT for the treatment of acute leukemia. Bone Marrow Transplant. 2011;46(2):285–90.CrossRef Ehlers SL, Gastineau DA, Patten CA, Decker PA, Rausch SM, Cerhan JR, Hogan WJ, Ebbert JO, Porrata LF. The impact of smoking on outcomes among patients undergoing hematopoietic SCT for the treatment of acute leukemia. Bone Marrow Transplant. 2011;46(2):285–90.CrossRef
30.
go back to reference Gajdos C, Hawn MT, Campagna EJ, Henderson WG, Singh JA, Houston T. Adverse effects of smoking on postoperative outcomes in cancer patients. Ann Surg Oncol. 2012;19(5):1430–8.CrossRef Gajdos C, Hawn MT, Campagna EJ, Henderson WG, Singh JA, Houston T. Adverse effects of smoking on postoperative outcomes in cancer patients. Ann Surg Oncol. 2012;19(5):1430–8.CrossRef
31.
go back to reference Steinberger E, Kollmeier M, McBride S, Novak C, Pei X, Zelefsky MJ. Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity. BJU Int. 2015;116(4):596–603.CrossRef Steinberger E, Kollmeier M, McBride S, Novak C, Pei X, Zelefsky MJ. Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity. BJU Int. 2015;116(4):596–603.CrossRef
32.
go back to reference Lugg ST, Tikka T, Agostini PJ, Kerr A, Adams K, Kalkat MS, Steyn RS, Rajesh PB, Bishay E, Thickett DR, et al. Smoking and timing of cessation on postoperative pulmonary complications after curative-intent lung cancer surgery. J Cardiothorac Surg. 2017;12(1):52.CrossRef Lugg ST, Tikka T, Agostini PJ, Kerr A, Adams K, Kalkat MS, Steyn RS, Rajesh PB, Bishay E, Thickett DR, et al. Smoking and timing of cessation on postoperative pulmonary complications after curative-intent lung cancer surgery. J Cardiothorac Surg. 2017;12(1):52.CrossRef
33.
go back to reference Zhang P, Nie X, Bie Z, Li L. Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma. Medicine. 2018;97(9):e0006.CrossRef Zhang P, Nie X, Bie Z, Li L. Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma. Medicine. 2018;97(9):e0006.CrossRef
34.
35.
go back to reference Obeidat NA, Hawari FI, Amarin R, Altamimi BA, Ghonimat IM. Educational needs of oncology practitioners in a regional Cancer Center in the Middle East-Improving the content of smoking cessation training programs. J Cancer Educ. 2017;32(4):714–20.CrossRef Obeidat NA, Hawari FI, Amarin R, Altamimi BA, Ghonimat IM. Educational needs of oncology practitioners in a regional Cancer Center in the Middle East-Improving the content of smoking cessation training programs. J Cancer Educ. 2017;32(4):714–20.CrossRef
36.
go back to reference Ayub H, Obeidat N, Leischow S, Glynn T, Hawari F. Jordan tobacco dependence treatment guidelines: rationale and development. East Mediterr Health J. 2016;21(11):844–50.CrossRef Ayub H, Obeidat N, Leischow S, Glynn T, Hawari F. Jordan tobacco dependence treatment guidelines: rationale and development. East Mediterr Health J. 2016;21(11):844–50.CrossRef
37.
go back to reference Simmons VN, Litvin EB, Jacobsen PB, Patel RD, McCaffrey JC, Oliver JA, Sutton SK, Brandon TH. Predictors of smoking relapse in patients with thoracic cancer or head and neck cancer. Cancer. 2013;119(7):1420–7.CrossRef Simmons VN, Litvin EB, Jacobsen PB, Patel RD, McCaffrey JC, Oliver JA, Sutton SK, Brandon TH. Predictors of smoking relapse in patients with thoracic cancer or head and neck cancer. Cancer. 2013;119(7):1420–7.CrossRef
38.
go back to reference Hopenhayn C, Christian WJ, Christian A, Studts J, Mullet T. Factors associated with smoking abstinence after diagnosis of early stage lung cancer. Lung Cancer. 2013;80(1):55–61.CrossRef Hopenhayn C, Christian WJ, Christian A, Studts J, Mullet T. Factors associated with smoking abstinence after diagnosis of early stage lung cancer. Lung Cancer. 2013;80(1):55–61.CrossRef
39.
go back to reference Alton D, Eng L, Lu L, Song Y, Su J, Farzanfar D, Mohan R, Krys O, Mattina K, Harper C, et al. Perceptions of continued smoking and smoking cessation among patients with Cancer. J Oncol Pract. 2018;14(5):e269–79.CrossRef Alton D, Eng L, Lu L, Song Y, Su J, Farzanfar D, Mohan R, Krys O, Mattina K, Harper C, et al. Perceptions of continued smoking and smoking cessation among patients with Cancer. J Oncol Pract. 2018;14(5):e269–79.CrossRef
40.
go back to reference Jaghbir M, Shareif S, Ahram M. Quitting smoking and utilization of smoking cessation services in Jordan: a population-based survey. East Mediterr Health J. 2014;20(9):538–46.CrossRef Jaghbir M, Shareif S, Ahram M. Quitting smoking and utilization of smoking cessation services in Jordan: a population-based survey. East Mediterr Health J. 2014;20(9):538–46.CrossRef
Metadata
Title
Smoking cessation care can translate to lower hazard of death in the short-run in cancer patients - a retrospective cohort study to demonstrate the value of smoking cessation services within the treatment phase of cancer
Authors
F. I. Hawari
N. A. Obeidat
D. Rimawi
K. Jamal
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Care
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5778-y

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine